iFuse Implant System
Commercial- Indications
- Sacroiliac joint dysfunction, Sacroiliac joint fusion
Company intelligence / Profile preview
SI-BONE’s proprietary minimally invasive surgical implants—most notably the iFuse Implant System—are supported by a robust body of clinical evidence including two randomized controlled trials and over 135 peer-reviewed publications. These studies demonstrate improved pain relief, patient function, quality of life, safety, durable effectiveness as well as biomechanical and economic benefits. The company’s products are widely adopted with more than 100,000 procedures performed globally by over 3,900 surgeons[8][9].
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SI-BONE.